Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
Hye Sung Won, Yong Seok Kim, Jeong Soo Kim, Eun Deok Chang, Sae Jung Na, In Yong Whang, Dong Soo Lee
Korean J Intern Med. 2020;35(6):1489-1496. Published online 2020 Feb 21 DOI: https://doi.org/10.3904/kjim.2019.031
Citations to this article as recorded by 
Temporality of change in Ki67 labelling following neoadjuvant systemic chemotherapy of breast cancer—the common drop often subsides with time
Ádám Ferenczi, Tamás Lantos, Gábor Cserni
Virchows Archiv.2025;[Epub] CrossRef
Do all patients with breast cancer benefit from neoadjuvant chemotherapy?
Kyoung Eun Lee
The Korean Journal of Internal Medicine.2020; 35(6): 1336. CrossRef